AKAP7

Across TCGA pan-cancer cohorts, AKAP7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKAP7 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher AKAP7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKAP7 expression acts as an unfavorable survival marker.

OV, HNSC, and LGG are the cancer types where AKAP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.204	0.541	.017	12	view →
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	9	view →
LGG	DFS	Median	All	0.118	0.832	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →
SKCM	OS	Median	All	0.605	0.788	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKAP7–OV (DFS)

Open the OV breakdown →